An open-label phase II study of the Hsp90 inhibitor ganetespib (STA-9090) as monotherapy in patients with advanced non-small cell lung cancer (NSCLC).
K. Wong
Research Funding - Synta
M. Koczywas
Consultant or Advisory Role - Genentech; Lilly
Honoraria - Genentech; Lilly
Research Funding - GlycaNova; Synta
J. W. Goldman
Research Funding - Synta
E. H. Paschold
Research Funding - Synta
L. Horn
Research Funding - Synta
J. M. Lufkin
Employment or Leadership Position - Synta
Stock Ownership - Synta
R. K. Blackman
Employment or Leadership Position - Synta
Stock Ownership - Synta
F. Teofilovici
Employment or Leadership Position - Synta
Stock Ownership - Synta
G. Shapiro
Research Funding - Synta
M. A. Socinski
Honoraria - Genentech; Lilly
Research Funding - Celgene; Genentech; Lilly; Pfizer; Synta